Tanomastat

• CAT Number: R004361
• CAS Number: 179545-77-8
• Molecular Formula: C23H19ClO3S
• Molecular Weight: 410.912
• Purity: ≥95%
• Target: MMP inhibitor
• Storage: -20°C
• IUPAC Name: (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid
• InChI: InChI=1S/C23H19ClO3S/c24-20-12-10-17(11-13-20)16-6-8-18(9-7-16)22(25)14-19(23(26)27)15-28-21-4-2-1-3-5-21/h1-13,19H,14-15H2,(H,26,27)/t19-/m1/s1
• InChIKey: JXAGDPXECXQWBC-LJQANCHMSA-N
• SMILES: C1=CC=C(C=C1)SCC(CC(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)Cl)C(=O)O

Tanomastat, also known as BAY 12-9566, is a biphenyl matrix metalloproteinase (MMP) inhibitor (MMPI) with potential antineoplastic activity. Tanomastat inhibits MMP-2, MMP-3, and MMP-9, inhibiting extracellular matrix degradation and potentially inhibiting angiogenesis, tumor growth and invasion, and metastasis. MMPs consist of at least 18 zinc-containing endo-proteinases that are capable of degrading collagen and proteoglycan.

Reference

1:Effects of azithromycin and tanomastat on experimental bronchiolitis obliterans. Krenn K, Gmeiner M, Paulus P, Sela N, Torres L, Zins K, Dekan G, Aharinejad S.J Thorac Cardiovasc Surg. 2015 Apr;149(4):1194-202. doi: 10.1016/j.jtcvs.2014.11.088. Epub 2014 Dec 4. PMID: 25595376 Free Article2:A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, Tu D, Sadura A, Brundage M, Seymour L.Gynecol Oncol. 2006 Aug;102(2):300-8. Epub 2006 Jan 25. PMID: 16442153